Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 21, 2022
Discovery & Translation
Oncorus’ synthetic RNA viruses for immunotherapy; plus Sisu’s small molecule for AML and more
BioCentury’s roundup of translational news
BioCentury | Dec 31, 2020
Distillery Therapeutics
Transcription factor HSF1 as a colon cancer target
DISEASE CATEGORY: Cancer
INDICATION: Colorectal cancer Inhibiting HSF1, a mediator of the proteotoxic stress response, could treat colorectal cancer induced by chronic inflammation. In colon samples
INDICATION: Colorectal cancer Inhibiting HSF1, a mediator of the proteotoxic stress response, could treat colorectal cancer induced by chronic inflammation. In colon samples
BioCentury | Jan 19, 2018
Tools & Techniques
Synthetic expressions
How synthetic biology could lead to a new generation of gene therapies
BioCentury | Aug 24, 2017
Translation in Brief
Unclumping TDP-43
Two ways TDP-43 forms aggregates in neurodegenerative disease
BioCentury | Mar 19, 2015
Distillery Therapeutics
Therapeutics: Heat shock transcription factor 1 (HSF1); MEK; proteasome
Items per page:
1 - 10 of 29